Advanced Filters
noise

Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,180 clinical trials
R Rachel Kingsford

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

The goal of this interventional clinical trial is to provide proof-of-principle data for the biologic activity of defactinib in combination with avutometinib in brain metastases from melanoma, and to define the potential role of the combination with mutant BRAF inhibitors or after BRAF/MEK inhibitors in BRAF V600E/K mutant tumors, in …

18 years of age All Phase 1/2
L Lung-Ji Chang, Ph.D

Combination Immunotherapy Targeting Melanoma

The purpose of this study is to assess the feasibility, safety and efficacy of combination immunotherapy based on CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines modified with GM-CSF and B7-2 (CD86) against melanoma, which targets CAR T specific surface antigens such as GD2, CTL specific …

18 - 75 years of age All Phase 1/2
J Jun Guo, Director

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.

18 years of age All Phase 1/2
J Jun Guo, Director

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination chemotherapy of investigator's choice in advanced melanoma patients with NRAS mutation who have received immunotherapy before. Subjects were stratified according to the baseline lactate …

18 years of age All Phase 3

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.

18 years of age All Phase 1/2
J Jun Guo, Director

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

This is a Phase Ib, open-label study to determine the safety and preliminary efficacy of PRJ1-3024 in China subjects with unresectable local advanced or metastatic melanoma

18 years of age All Phase 1/2
X Xian'an Li

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

This is a Phase II, open-label, randomized, multi-center study to assess the efficacy and safety of IBI363 monotherapy compared to Pembrolizumab in the treatment of patients with unresectable locally advanced or metastatic mucosal or acral melanoma who had not previously received systemic therapy.

18 years of age All Phase 2
D Danielle Bednarz, RN, BSN

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells and does not infect healthy cells. This results in tumor …

18 years of age All Phase N/A
L Lung-Ji Chang, Ph.D

NG2 and DLL3 CAR-T Cells Targeting Melanoma

The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.

18 - 75 years of age All Phase 1/2
J Jennifer McQuade

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

To Determine the feasibility, compliance and adherence to PreFED intervention in resectable melanoma patients initiating neoadjuvant Ipi/Nivo.

18 years of age All Phase 2

Simplify language using AI